Abelacimab

Phase 3Monoclonal antibody

AAnthos Therapeutics, Inc.

Abelacimab is one of 47 biologic programs targeting Atrial Fibrillation (AF). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial Fibrillation (AF)Recruiting

Genitourinary CancerActive, not recruiting

Atrial FibrillationActive, not recruiting

Atrial Fibrillation (AF)Phase 3

Recruiting

Genitourinary CancerPhase 3

Active, not recruiting

Atrial FibrillationPhase 2

Active, not recruiting

Competition

Competitive Landscape

137 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Abelacimab

AAnthos Therapeutics, Inc.

Phase 3

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Coumadin

3 5

Imbruvica

PPharmacyclics LLC.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 8

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Brukinsa

BBeOne Medicines

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Genitourinary Cancer

NCT05171075

Q4 2027

Phase 3Recruiting

Atrial Fibrillation (AF)

NCT05712200

Q4 2028

Phase 2Active, not recruiting

Atrial Fibrillation

NCT04755283

Q4 2030

Phase 3Not yet recruiting

Atrial Fibrillation (AF)

NCT07739888

Clinical

Trials by Indication[1]

Atrial Fibrillation (AF)2 trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Not yet recruiting· Novartis logo

Novartis·Phase 3·NCT07739888·2,500 enrolled

Recruiting·AAnthos Therapeutics, Inc.·Phase 3·NCT05712200·2,500 enrolled

Atrial Fibrillation1 trial

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Active, not recruiting·AAnthos Therapeutics, Inc.·Phase 2·NCT04755283·1,287 enrolled

Genitourinary Cancer1 trial

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Active, not recruiting·AAnthos Therapeutics, Inc.·Phase 3·NCT05171075·417 enrolled

Treatment1 trial

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Terminated·AAnthos Therapeutics, Inc.·Phase 3·NCT05171049·1,150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Abelacimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abelacimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abelacimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Anthos Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AAnthos Therapeutics, Inc.

Abelacimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Q4 2030

Trials by Indication[1]

Atrial Fibrillation (AF)2 trials

Atrial Fibrillation1 trial

Genitourinary Cancer1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News